🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Germany / NCT07434349
Recruiting Not applicable

Exercise Timing and Postprandial Glucose Responses

NCT07434349 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2026-04-01
Last updated
2026-04-20

Condition(s) studied

Exercise TimingPostprandial Glucose

Investigational drug(s) / intervention(s)

Timed Endurance ExerciseNo Exercise Control

Timed Endurance Exercise: The exercise intervention consists of a 45 minute continuous outdoor run performed on a standardized route. Participants are instructed to maintain a consistent running pace across all exercise conditions. Exercise intensity is standardized using a target heart rate corresponding to 75 to 85 percent of maximal heart rate, and participants must be able to complete 45 minutes of continuous running at this intensity without stopping. Heart rate, duration, distance, and pace are recorded using a heart rate monitor and GPS enabled device. Ambient temperature and precipitation are recorded for each session. Exercise sessions may be rescheduled in cases of extreme weather or acute illness.

No Exercise Control: This intervention involves a non-exercise control condition

Study summary

This interventional crossover study examines the effect of exercise timing relative to meal intake on postprandial glucose responses in healthy, physically active young adults. Participants complete five experimental conditions involving endurance exercise performed before or after breakfast or dinner, as well as a non-exercise control condition, while wearing a continuous glucose monitoring device.

Postprandial glucose responses are assessed for the three consecutive meals following each exercise session. Following morning exercise, outcomes are assessed after breakfast, lunch, and dinner on the same day. Following evening exercise, outcomes are assessed after dinner on the same day and after breakfast and lunch on the subsequent day. All meals are standardized and consumed at fixed clock times.

Eligibility

Sex
ALL
Min age
18 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age 18 to 35 years * Body mass index 18.5 to 24.9 kg per square meter * Able to complete 45 minutes of continuous running at an intensity corresponding to 75 to 85 percent of maximal heart rate without stopping * Engages in regular endurance-type physical activity * Habitual waking times are compatible with the fixed breakfast time of 08:00 * Willing and able to comply with all study procedures, including standardized meals, exercise sessions, behavioral restrictions, and continuous glucose monitoring * For female participants: non-pregnant and using stable hormonal contraception for at least 3 months Exclusion Criteria: * Acute or chronic illness * Metabolic disorders or conditions associated with altered glucose or lipid metabolism * Use of medications known to interfere with glucose metabolism or study outcomes * Intolerance or allergy to components of the standardized study diets * Pregnancy or breastfeeding * Body mass index greater than or equal to 25 kg per square meter * Current or past eating disorder, or any medical condition or medication that could affect appetite regulation, glucose regulation, or make vigorous endurance exercise unsafe * Current smoking or use of nicotine-containing products

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Technical University of Munich München Bavaria Recruiting

More Technical University of Munich trials in Germany

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07434349 on ClinicalTrials.gov ↗ ← All trials in Germany